Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 2/20 | 0.46 |
| ▸ | ATP4A | P20648 | 1/20 | 0.36 |
| ▸ | ATP4B | P51164 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 2/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | USP2 | O75604 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | RECQL | P46063 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12017482 | 0.80 | SLC6A4 (0.41) | POLBMEN1KMT2AMAPTKDM4E | |
| SCHEMBL7822927 | 0.76 | TAAR1 (0.41) | MEN1KMT2A | |
| SCHEMBL5816301 | 0.76 | C1R (0.38) | — | |
| SCHEMBL9057228 | 0.76 | AR (0.43) | ARATP4AATP4BL3MBTL1ALDH1A1 | |
| SCHEMBL3145757 | 0.76 | HSPA5 (0.52) | MAPTGAA | |
| SCHEMBL3149895 | 0.75 | AR (0.47) | ARMAPTL3MBTL1KDM4EALDH1A1 | |
| SCHEMBL12017402 | 0.75 | APP (0.49) | MEN1KMT2AMAPTALDH1A1HSD17B10 | |
| SCHEMBL1249225 | 0.73 | ADRA2A (0.53) | MAPTKDM4EALDH1A1HPGDGAA | |
| SCHEMBL3338194 | 0.73 | APP (0.40) | POLBMEN1KMT2AMAPTALDH1A1 | |
| SCHEMBL10620438 | 0.73 | KDM4E (0.43) | ARPOLBMEN1KMT2AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120220577-A1 | GLYCINE B ANTAGONISTS | MERZ PHARMA GMBH & CO KGAA | 2012-08-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120220577-A1 | GLYCINE B ANTAGONISTS | GLRB, GRIN2B, GLRA2 | AR 3375/4885ATP4A 2166/4885ATP4B 1478/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.